Liver Involvement is Associated with Higher Risk of Rapidly Progressive Interstitial Lung Disease and Mortality in Anti-Melanoma Differentiation-Associated Gene 5 Antibody- Positive Dermatomyositis
DOI: https://doi.org/10.2147/jir.s462721
IF: 4.5
2024-05-18
Journal of Inflammation Research
Abstract:Xin Yang, 1 Xiaoguang Cui, 1 Xiao Yang, 2 Bincheng Ren, 1 Xiaojing Cheng, 1 Xinrui Zhao, 1 Shanshan Liu, 1 Tian Tian, 1 Hui Zhao, 1 Li Qu, 1 Xueyi Li 1 1 Department of Rheumatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, People's Republic of China; 2 Scientific Research Center and Precision Medical Institute, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, People's Republic of China Correspondence: Xueyi Li, Department of Rheumatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, People's Republic of China, Tel +86 13992891987, Fax +86 02987679832, Email Purpose: This study aimed to assess liver involvement and investigate its correlation with rapidly progressive interstitial lung disease (RP-ILD) and mortality in anti-melanoma differentiation-associated gene 5 antibody-positive (anti-MDA5 positive) DM patients. Patients and Methods: This retrospective study included 159 patients diagnosed with anti-MDA5 positive DM or anti-synthetase syndrome (ASyS). Clinical features and laboratory findings were compared between patients with anti-MDA5 positive DM and patients with ASyS. In the anti-MDA5 positive DM cohort, clinical features and laboratory findings between patients with liver involvement and without liver involvement were further compared. The effects of liver involvement on the overall survival (OS) and development of RP-ILD were also analyzed using Kaplan–Meier method and Cox regression analysis. Results: Levels of serum aspartate aminotransferase (AST), alanine transaminase (ALT), γ-glutamyl transferase (γGT) and alkaline phosphatase (ALP) were all significantly higher in patients with anti-MDA5 positive DM than those in patients with ASyS. In our cohort of anti-MDA5 positive DM patents, 31 patients (34.4%) were complicated with liver involvement. Survival analysis revealed that serum ferritin > 1030.0 ng/mL (p 103.0 U/l (p 49.0 U/l (p 82.0 U/l (p 133.0 U/l (p 474.0 U/l (p< 0.001), plasma albumin (ALB) < 35.7 g/l (p 2.80 μmol/l (p=0.002) predicted poor prognosis. The incidence of RP-ILD increased remarkably in patients with liver involvement compared to patients without liver involvement (58.1% vs 22.0%, p=0.001). Multivariate analysis revealed that elevated serum ALT level was an independent risk factor for mortality (HR 6.0, 95% CI 2.3, 16.2, p< 0.001) and RP-ILD (HR 5.9, 95% CI 2.2, 15.9, p< 0.001) in anti-MDA5 positive DM patents. Conclusion: Liver involvement is common in patients with anti-MDA5 positive DM. Elevated serum ALT level was an independent risk factor for RP-ILD and mortality in patients with anti-MDA5 positive DM. Keywords: anti-melanoma differentiation-associated gene 5 antibody, liver involvement, ferritin, macrophage, interstitial lung disease, dermatomyositis Idiopathic inflammatory myopathy (IIM) constitutes a large spectrum of autoimmune disorders, which can be classified into several groups: dermatomyositis (DM), anti-synthetase syndrome (ASyS), immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis (PM) and overlap myositis 1 . A growing body of evidence indicated that myositis-specific antibodies have been associated with distinctive clinical phenotypes. 2 RNA helicase encoded by anti-melanoma differentiation-associated gene 5 (MDA5) was identified as the major autoantigen of anti-MDA5 antibody. 3 MDA5 is a cytosolic protein, essential for antiviral host immune responses, which functions as a virus RNA sensor. 4 Anti MDA5 antibody (anti-MDA5) positive DM is characterized by clinically amyopathic DM and rapidly progressive interstitial lung disease (RP-ILD), which is correlated with an aggressive course and poor prognosis. Skin ulceration and palmar papules are typical skin features of anti-MDA5 positive DM. 5,6 The prevalence of ILD reported in anti-MDA5 positive DM ranged from 50 to 100%. 7 Anti-MDA5 positive DM has been frequently reported to be refractory to common combined immunosuppressive therapies, and the 6-month mortality of RP-ILD was reported to be as high as 50%. 8 Consequently, exploring the characteristics and risk factors for RP-ILD and mortality is still urgently needed. Liver injury and elevated liver enzymes in anti-MDA5 positive DM patients were reported in many studies. 4,9–11 Jiang et al reported that 36.4% patients with anti-MDA5 positive DM presented with liver involvement. 9 However, studies focus -Abstract Truncated-
immunology